We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Sponsors Should Ensure Quality in Pharmacogenomic Data
FDA: Sponsors Should Ensure Quality in Pharmacogenomic Data
August 31, 2007
Sponsors of clinical trials using pharmacogenomic data should use proper methodology to ensure high quality when they submit gene expression data from microarrays, according to a draft guidance from the FDA.